TriNetX and Regeneron Forge Strategic Partnership for Health Data Research and Development TriNetX and Regeneron have entered a strategic collaboration to access anonymized electronic health records from 300 million patients, enhancing biomedical research.

TriNetX and Regeneron Forge Strategic Partnership for Health Data Research and Development #USA #health_data #TriNetX #Regeneron #Tarrytown,_New_York

TriNetX and Regeneron Form Strategic Collaboration on Health Data Utilization A new collaboration between TriNetX and Regeneron aims to enhance health research by providing access to anonymized health records of 300 million patients.

TriNetX and Regeneron Form Strategic Collaboration on Health Data Utilization #USA #Tarrytown #health_data #TriNetX #Regeneron

TriNetX Partners with Regeneron to Enhance Research through Access to Health Records The collaboration between TriNetX and Regeneron will leverage 300 million de-identified EHRs to enhance drug development and digital health solutions.

TriNetX Partners with Regeneron to Enhance Research through Access to Health Records #USA #health_data #TriNetX #Regeneron #Tarrytown,_New_York

TriNetX and Regeneron Partner to Revolutionize Health Data Utilization for Drug Development TriNetX and Regeneron have formed a groundbreaking partnership to enhance drug discovery through extensive electronic health records, benefiting the healthcare sector.

TriNetX and Regeneron Partner to Revolutionize Health Data Utilization for Drug Development #USA #digital_health #Tarrytown #TriNetX #Regeneron

Illumina and Nashville Biosciences Expand Genomic Discovery Alliance with Regeneron Membership Illumina and Nashville Biosciences have boosted their Alliance for Genomic Discovery with the addition of Regeneron and new proteomics data offerings.

Illumina and Nashville Biosciences Expand Genomic Discovery Alliance with Regeneron Membership #USA #San_Diego #Illumina #Regeneron #Nashville_Biosciences

リジェネロン、AAAAI 2026で免疫領域36演題発表へ──猫・シラカバ花粉アレルギー第3相データ初公開、デュピルマブ新解析も提示 | STELLANEWS.LIFE STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見 | STELLANEWS.LIFE（ステラニュース・ライフ）は、科学や技術、医薬品分野における最新の研究成果や発見

リジェネロン、AAAAI 2026で免疫領域36演題発表へ
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI 2026

stellanews.life/technology/8...

AI impact rating（reference only）: ★★★★☆
This is an experimental indicator and not a guarantee of accuracy.

#AAAAI #Allergy #Dupilumab #Phase3 #Regeneron

Groundbreaking Insights on Sex Differences in Rare Cholesterol Disorder Published in AJPC The AJPC's latest issue features a pivotal study revealing significant sex-based differences in cholesterol treatment response among HoFH patients, marking a crucial step forward in cardiovascular research.

Groundbreaking Insights on Sex Differences in Rare Cholesterol Disorder Published in AJPC #United_States #Boulder #Regeneron #AJPC #HoFH

COPD patients will get access to Dupixent via NHS Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

#COPDpatients #Dupixent #dupilumab #NHS #chronicobstructivepulmonarydisease #COPD #biologics #Sanofi #Regeneron #uncontrolledCOPD #lungdisease #COPDtherapies #NICEfinaldraftguidance #COPDflareups #COPDdiagnosis #NICE #NHScostsavings #uncontrolledCOPD #COPDcare
zurl.co/7i5io

STAT+: On Day 4 of JPM, a chat with Regeneron’s George Yancopoulos, an IPO forecast, and all eyes on J&J It's the last special edition of The Readout at #JPM26 — full of news and notes about biotech.

Dr. @ertrunnell.bsky.social thanks for posting. While there is much yet to do, think in not too distant future #GigaTIME will have a major impact in tailoring therapies to patients with #cancer #GSK #Astrazeneca #Regeneron #Abbvie #incyte #FDA #NCI #FinishCancer

The real reason Trump's face is orange: #netherlands youtu.be/_kmadDpTREw

#gregshapiro #dutchamerican #boomchicago #howtobedutch #standup #climate #goodnews #comedyshow #corporateevents #regeneron #covid @Regeneron #trump #dutch

ASH: Regeneron makes frontline case for Lynozyfic in myeloma Regeneron's BCMAxCD3 bispecific Lynozyfic is the first drug in the class to show efficacy as a monotherapy in first-line multiple myeloma treatment.

#Regeneron has been a bit of a latecomer in the market for #BCMA-directed therapies for #multiplemyeloma, but is pushing to catch up with rival therapies from Johnson & Johnson and Pfizer.

FDA announces first nine recipients of priority drug review vouchers FDA announced the first nine recipients of priority review vouchers, which offers expedited drug review to products aligned with national health priorities.

FDA announces first nine recipients of priority drug review vouchers.. statnews.com/2025/10/16/f... #pharma #FDA #vouchers #Sanofi #Regeneron

Regeneron's Libtayo stakes out new territory in skin cancer Regeneron's Libtayo has become the first checkpoint inhibitor to be cleared by the FDA as an adjuvant treatment for cutaneous squamous cell carcinoma.

#Regeneron #Libtayo #cemiplimab #skincancer #Squamouscellcarcinoma #checkpointinhibitor #FDA #cutaneoussquamouscellcarcinoma #CSCC #basalcellcarcinoma #nonsmallcelllungcancer #cervicalcancer #highriskCSCC #KEYNOTE630study #CPOSTstudy #Libtayotreatedpatients #PD1PDL1inhibitors
zurl.co/9toKK

Regeneron drug on track to be second FOP treatment There is only one approved drug for ultra-rare disease FOP on the market, but Regeneron is hoping to add a second.

There is only one approved drug for ultra-rare disease fibrodysplasia ossificans progressiva (#FOP) on the #USmarket, but #Regeneron is hoping to add to that tally.

Regeneron advances allergy pipeline with positive Phase 3 trial results Investing.com -- Regeneron Pharmaceuticals Inc (NASDAQ:REGN) announced positive results from two Phase 3 trials evaluating first-in-class antibody-blockers targeting cat and birch allergies. The pharmaceutical company reported that both trials successfully met their primary and secondary endpoints. The combination therapy was well-tolerated with no serious adverse events reported during the studies. Following these encouraging results, Regeneron plans to advance its allergy pipeline with additional Phase 3 development scheduled to begin in the first half of 2026. The trials represent progress in Regeneron’s efforts to develop novel treatments for common allergies using antibody-blocking technology, potentially offering new options for allergy sufferers. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. 3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads. Is REGN part of an AI-powered winning strategy? ProPicks AI evaluates REGN alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if REGN is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Click Subscribe #Regeneron #AllergyResearch #Phase3Trials #Pharmaceuticals #ClinicalTrials

#Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder #generalisedmyastheniagravis (gMG), cemdisiran, which can be dosed just four times a year.

pharmaphorum.com/news/regener...

Major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, FDA finds A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a recent inspection report.

Major U.S. drug making plant owned by Novo didn't properly investigate cat hair, pests and other problems, FDA finds.. statnews.com/pharmalot/20... #pharma #FDA #manufacturing #biotech #medicines #Catalent #Novo #Regeneron

Rothschild bullish on Regeneron as pipeline strength outweighs Eylea decline Investing.com -- Rothschild initiated coverage of Regeneron Pharmaceuticals with a Buy rating and a $890 price target, saying the drugmaker’s pipeline potential is being overlooked amid concerns over its key eye drug Eylea. The bank said investor sentiment toward biotechnology has been weak, with the sector underperforming the S&P 500 since 2016 and funding conditions remaining tight. But it noted the industry has rebounded from past downturns, including a decade-long slump after the early 2000s tech bubble burst. Regeneron’s shares have dropped sharply since peaking in August 2024, hurt by slowing Eylea sales due to competition from Roche’s Vabysmo, limited uptake of its high-dose version, and the pending arrival of biosimilars. Sales and earnings forecasts for 2025 have been cut by 13% and 30% respectively. The stock also fell 19% in May after mixed data from its chronic obstructive pulmonary disease drug itepekimab. Rothschild called the sell-off overdone, arguing that investors are focusing too heavily on Eylea’s weakness while overlooking the breadth of the company’s development pipeline. The bank identified 15 experimental drugs it expects could each add at least $500 million in annual sales by 2031, with seven potentially generating $1–2 billion. It said the market’s tendency to assign no value to unapproved drugs, even on a probability-adjusted basis, understates Regeneron’s prospects. “Despite recent setbacks, this is about the pipeline more than the marketed portfolio,” Rothschild wrote, echoing comments from Regeneron’s chief executive earlier this year.

Click Subscribe #Rothschild #Regeneron #Eylea #pharmaceuticals #biotech

Pharmalittle: We're reading about an FDA rejection, the Big Beautiful Bill's cost, and much more The FDA's top regulator of cancer drugs interceded in a review of a Replimune skin cancer therapy, contributing to its rejection

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about an FDA rejection, the Big Beautiful Bill’s cost, and much more news.. statnews.com/pharmalot/20... #pharma #biotech #medicine #FDA #Medicare #HIV #patents #transparency #Replimune #Gilead #Regeneron

Boehringer raises hope of oral drug for diabetic eye disease Boehringer has started a phase 2 trial of an oral therapy that could help people with diabetic macular oedema avoid regular injections into the eye.

#Ophthalmology #BoehringerIngelheim #diabeticeyedisease #diabeticmacularoedema #DME #BI1815368 #THULITEstudy #centreinvolvedDME #VEGFtargetingdrugs #Roche #Vabysmo #faricimab #Lucentis #ranibizumab #Bayer #Regeneron #Eylea #aflibercept #Susvimo #ranibizumab
pharmaphorum.com/news/boehrin...

Pharmalittle: We're reading about Regeneron's patent maneuvers, FDA rejection letters, and lots more A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to thwart competition

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about Regeneron’s patent maneuvers, FDA rejection letters & lots more news.. statnews.com/pharmalot/20... #pharma #Covid #vaccines #patents #biosimilars #weight #obesity #abortion #advertising #eyes #humanrights #Pfizer #Amgen #Regeneron

How Regeneron, maker of a best-selling eye drug, is using patent tactics to try to thwart competition A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using patents to thwart competition.

“Only in the U.S. do we allow this game, this procedural tool," says Sean Tu, a University of Alabama law school professor who studies pharmaceutical patent issues.. "...It's a dumb system.”
statnews.com/pharmalot/20... #pharma #biotech #patents #eylea #Regeneron #Amgen

Apogee Surges 33% Premarket After Strong Phase 2 Eczema Results Apogee Therapeutics (Nasdaq: APGE) soared as much as 33% premarket after reporting positive topline data from its Phase 2 trial of APG777 in moderate-to-severe

Apogee Therapeutics #APGE shares surged pre-market after its eczema drug APG777 delivered best-in-class results in a Phase 2 trial. The IL-13 antibody hit all endpoints and could challenge Dupixent, co-developed by #sanofi ( #SNY) and #Regeneron ( #REGN)...
prismmarketview.com/apogee-surge...

FirstWord

#AbbVie #Biogen #BMS #CapstanTherapeutics #CARTtherapies #Gilead #JnJ #Novartis #ParvusTherapeutics #SAGETherapeutics #SupernusPharmaceuticals #UmojaBiopharma #4DMolecularTherapeutics #4DMT #Regeneron #Tecvayli #GSK #Dizal #UnicyciveTherapeutics #AstraZeneca
firstwordpharma.com/story/5978127

Pharmalittle: We're reading about a memo on RFK Jr., a Novartis blockbuster's failed trial, and more A memo that purports to summarize a meeting held by members of a biotech trade group suggests deep concern about RFK Jr.’s stance on vaccines

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a memo on RFK Jr., a Novartis blockbuster’s failed trial & more news.. statnews.com/pharmalot/20... #pharma #vaccines #Medicare #Medicaid #fraud #HHS #CDC #FDA #DOJ #RSV #Novartis #Regeneron

US FDA approves Regeneron’s blood cancer therapy Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Click Subscribe #FDAApproval #BloodCancer #Regeneron #CancerResearch #Oncology

Sanofi and Regeneron’s Dupixent gets FDA approval for rare skin disease Investing.com -- Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) Pharmaceuticals received Food and Drug Administration approval for their anti-inflammatory drug Dupixent to treat a rare skin disease, marking the eighth indication in the U.S. for this blockbuster medicine. The FDA approved Dupixent on Friday as a treatment for adult patients with bullous pemphigoid, according to the companies. This rare skin disease primarily affects elderly people and causes itching, blisters, lesions, and skin reddening. The approval was based on results from a pivotal study that demonstrated more patients taking Dupixent achieved sustained disease remission and itch reduction compared to those on placebo. The FDA evaluated the drug under priority review, a process reserved for medicines that may bring significant improvements to the treatment of serious conditions. Bullous pemphigoid represents the eighth FDA-approved indication for Dupixent in the United States. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. SASY: A Bull or Bear Market Play? Don't miss out on the next big opportunity! Stay ahead of the curve with ProPicks – 6 model portfolios fueled by AI stock picks with a stellar performance this year.. In 2024 alone, ProPicks' AI identified 2 stocks that surged over 150%, 4 additional stocks that leaped over 30%, and 3 more that climbed over 25%. That's an impressive track record. With portfolios tailored for Dow stocks, S&P stocks, Tech Stocks, and Mid Cap stocks, you can explore various wealth-building strategies. So if SASY is on your watchlist, it could be very wise to know whether or not it made the ProPicks lists.

Click Subscribe #Sanofi #Regeneron #Dupixent #FDApproval #RareDiseases

$305M Power Play: Anne Wojcicki Outbids Regeneron for 23andMe Anne Wojcicki has outbid Regeneron with a $305 million offer to reclaim 23andMe, the genetic health tech company she co-founded.

In a dramatic turn of events, #23andMe co-founder Anne Wojcicki has outbid #Regeneron $256M to reclaim her genetic testing company through her nonprofit #TTAM Research Institute for $305 million.

athletechnews.com/305m-power-p...

How to delete your 23andMe data | TechCrunch 23andMe holds millions of customers' genetic information. Here's what you can do to protect your data.

How to delete your 23andMe data

if you previously agreed to #23andMe and 3rd-party researchers using your genetic data, you can withdraw consent from the Research and Product Consents section in account settings

#Regeneron #BigPharma #DNA #genetics #business #bankruptcy #privacy #biotech